Dana-Farber Research News 07.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.

By
July 1, 2026
36 min

Dana-Farber

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#2

Translational Breast Cancer Research Consortium

N/A, N/A
Key Differentiators
- Oncology
#3

German CLL Study Group

N/A, N/A
Key Differentiators
- Oncology
#4

UK Biobank

N/A, N/A
Key Differentiators
- Oncology
#5

French National Histiocytosis Registry

N/A, N/A
Key Differentiators
- Oncology

Original Source(s)

Dana-Farber

Dana-Farber Research News 07.01.2026

by
July 1, 2026

Related Content

Dana-Farber

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.